Latest Commercial Execution News

Pure Foods Tasmania appoints Robert Knight as CEO and Managing Director, aligning leadership with shareholder interests amid ongoing growth and turnaround efforts.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

HIQ Limited has locked in non-dilutive funding from the Victorian Government to underpin a $4.9 million project expanding its manufacturing and research footprint in Victoria, supporting its global growth ambitions.

ION Video has appointed former Apple executive Kelli Richards as its inaugural Advisory Board member, aiming to leverage her Silicon Valley connections and media tech expertise to accelerate commercialisation.

Saluda Medical’s Australian arm has secured ASIC approval to bypass standalone audited financial reports, cutting costs and streamlining compliance.

Merino & Co. secures a significant AUD 1.1 million order from its China distribution partner, marking the first major commercial milestone under its exclusive China distribution agreement and signalling growing demand for its wool products.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Proteomics International Laboratories (ASX:PIQ) has denied any undisclosed material information following a sharp share price drop and heightened trading activity, pointing instead to recent strategic updates and organisational changes.

Orica Limited posted its strongest half-year EBIT in over 20 years at $512 million, driven by premium product demand and strategic acquisitions including Nelson Brothers. The company also initiated a $100 million cost reduction program and declared a 28.5 cent interim dividend.

BrainChip detailed significant progress in its neuromorphic AI technology and commercial strategy at its 2026 AGM, highlighting the AKD1500 chip launch and expanding defense and industrial collaborations.

IMEXHS Limited kicked off FY26 with a 13% revenue increase and a strategic pivot to an AI-native radiology workflow platform, securing major contracts in Latin America and advancing proprietary AI agents.